Documentdetail
ID kaart
oai:pubmedcentral.nih.gov:1108...
Onderwerp
Original ResearchAuteur
Rath, Louise Yeh, Wei Zhen Roldan, Angie Wesselingh, Robb Zhong, Michael Tan, Tracie Seery, Nabil Bridge, Francesca Foong, YiChao Skibina, Olga Nesbitt, Cassie Butzkueven, Helmut Monif, Mastura van der Walt, AnnekeLangue
enEditor
BMJ Publishing Group
Categorie
BMJ Neurology Open
Jaar
2024
vermelding datum
11-06-2024
Trefwoorden
pwnic eligible pwms assess received covid-19 tixagevimab/cilgavimab uptakeBeschrijving
BACKGROUND: In Australia, tixagevimab/cilgavimab 150 mg/150 mg was a government-funded pre-exposure prophylaxis for COVID-19 people with multiple sclerosis (pwMS) and other neuroimmunological conditions (pwNIc) treated with anti-CD20 antibodies or sphingosine-1-phosphate receptor modulators were eligible.
OBJECTIVE: To analyse the roll-out, uptake and real-world efficacy of tixagevimab/cilgavimab in the prevention and severity of COVID-19.
To assess compliance with uptake depending on the location of delivery.
METHODS: We undertook a single-centre study.
440 pwMS and pwNIc were eligible.
Logistic regression was used to assess predictors of COVID-19 during follow-up and to assess predictors of uptake among those who consented.
RESULTS: Of the eligible pwMS and pwNIc in our service, 52.7% (233/440) requested a consultation and were included in this study.
Consultation resulted in 71.7% of people (167/233) receiving the treatment.
Of these, 94.0% (157/167) had received three or more COVID-19 vaccines.
Among those who received a single dose of tixagevimab/cilgavimab, 19.16% (32/167) tested positive for COVID-19 during the observational window.
The majority of these were on ocrelizumab (68.8% (22/32)).
None of those with COVID-19 required hospitalisation or supplemental oxygen.
There was no difference in odds of COVID-19 during the observation period between those who received and did not receive tixagevimab/cilgavimab (adjusted OR, aOR 2.16 (95% CI 0.82 to 6.85), p=0.43).
Uptake of tixagevimab/cilgavimab was highest when offered at the hospital infusion centre (aOR 3.09 (95% CI 1.08 to 9.94) relative to referral to the local pharmacy, p=0.04).
CONCLUSION: Tixagevimab/cilgavimab administration did not protect against subsequent COVID-19 in our cohort.
Compliance with uptake was influenced by administration location.
Rath, Louise,Yeh, Wei Zhen,Roldan, Angie,Wesselingh, Robb,Zhong, Michael,Tan, Tracie,Seery, Nabil,Bridge, Francesca,Foong, YiChao,Skibina, Olga,Nesbitt, Cassie,Butzkueven, Helmut,Monif, Mastura,van der Walt, Anneke, 2024, Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic, BMJ Publishing Group
Real-world efficacy, roll-out and uptake of intramuscular tixagevimab/cilgavimab as COVID-19 pre-exposure prophylaxis in people with multiple sclerosis and neuroimmunological conditions during the COVID-19 pandemic
pwnic eligible pwms assess received covid-19 tixagevimab/cilgavimab uptake
